ABSTRACT
Objective To study the clinical effect of aripiprazole combined with lithium carbonate in the treatment of acute mania .Methods 72 patients with acute mania were selected in this research .According to the order of admission,the patients with odd numbers were selected as the control group (n=36),and the patients with even numbers were selected as the observation group (n=36).The control group was treated with clozapine combined with lithium carbonate ,the observation group was treated by aripiprazole combined with lithium carbonate .The safety and efficacy of the treatment were evaluated by BRMS score , effective rate , incidence rate of adverse reaction etc .Results After treatment for 1 week,2 weeks,the BRMS scores of the observation group were (21.23 ±2.22)points and (20.02 ±2.12)points,which were significantly lower than those of the control group (t=4.0390,4.0025,all P<0.05).After treatment for 4 and 8 weeks,the BRMS scores of the two groups were similar .The effective rate of the observation group was 94.44%,which of the control group was 91.67%,the difference was not statistically signifi-cant (P>0.05).The incidence rate of adverse reactions of the observation group was 19.44%,which was significantly lower than 41.67% of the control group,the difference was statistically significant (χ2 =11.6446,P<0.05) .Conclusion Aripiprazole combined with lithium carbonate has similar effect with clozapine combined with lithium carbonate in the treatment of acute mania ,but the combination therapy of aripiprazole and lithium carbonate can effec -tively alleviate the symptoms of the disease ,and with less adverse reaction ,high safety,which can be promoted and applicated in clinical .
ABSTRACT
Objective To investigate the effect of Avastin (bevacizumab) combined with preoperative FOLFOX neoadjuvant chemotherapy on the prognosis of patients with locally advanced rectal cancer (LARC).MethodsA total of 80 cases of patients with LARC treated with total mesorectal excision (TME) in our hospital from January 2013 to January 2016 were randomly divided into the control group and the observation group, 40 cases in each group.The control group were treated with preoperative FOLFOX chemotherapy while the observation group were treated with bevacizumab injection, based on the treatment in the control group.21 days was a cycle of chemotherapy, and both groups were treated for at least 4 cycles.After 6 cycles of chemotherapy, operation was carried out, following TEM principle.The short-term and long-term prognosis, rate of R0 resection, the incidence of postoperative complications and side effects of chemotherapy were compared between the two groups.ResultsThere was no significant difference between the two groups in the good response rate of chemotherapy, the rate of R0 resection, the incidence of postoperative complications, the 1-year and 3-year survival rates and 1-year disease-free survival rate.The incidence rates of gastrointestinal reactions and bone marrow suppression in the observation group were 52.5% and 52.5%, respectively while in the control group were 25.0% and 20.0%, respectively (P<0.05), but there was no significant difference in the incidence rates of grade Ⅲ~Ⅳ gastrointestinal reaction and bone marrow suppression between the observation group and the control group (5.0% and 15.0% vs 2.5% and 5.0%).The 3-year disease-free survival rate of the observation group was higher than that of the control group (82.5% vs 60.0%) (P<0.05).ConclusionThe application of bevacizumab combined with preoperative FOLFOX chemotherapy in the treatment of LARC can improve the 3-year disease-free survival rate, without increasing postoperative adverse reactions and serious side effects of chemotherapy.
ABSTRACT
Objective To compare the efficacy and prognosis of epirubicin combined with paclitaxel and epirubicin combined with docetaxel in the treatment of breast cancer.Methods Patients in the study group were treated with epirubicin and paclitaxel, while the control group was treated with epirubicin plus docetaxel.Results The two groups of breast cancer patients by the end of the treatment were valid for 5 years of follow-up, five year survival rate(86.67%)than the control group(68.89%), the study group the recurrence rate(4.44%)than in the control group(15.56%), the data had significant differences(P<0.05).Conclusion The epirubicin is conducive to breast cancer patients for better disease control effect and prognosis than star, paclitaxel combined with chemotherapy.
ABSTRACT
Objective BALB/C mice were inoculated subcutaneously with hepatoma 22 (H22) cells, and the treatment effect of thalidomide and intratumor injection of ethanol extract of Scutellaria Barbata (SB) on tumor growth were evaluated. Methods In vitro, mouse H22 liver cells were cultivated, and H22 cells in the logarithmic growth phase were tested. SB was extracted in the ethanol recirculation. A total of 28 BALB/C male mice inoculated subcutaneously with H22 cells were randomly divided into 4 groups, 7 mice per group. Group A:intragastric administration with thalidomide. Group B:SB intratumor injection. Group C:combination of thalidomide and SB with the same administration as Group A and Group B. Group D (control group):1% Ethanol 0.2～0.5 mL intratumor injection. Tumor volumes of four groups were observed and the tumors were weighed. The microvessel densities (MVD) of all transplantation tumors were measured by immunohistochemical staining with anti-CD31 monoclonal antibody. Results There were statistically significant differences between Group C and Group A (P 0.05). The studies showed statistically differences between Group C and Group A (P
ABSTRACT
OBJECTIVE:To observe the influence of Valsartan on the serum ET,CGRP levels,urinary protein and Q - Td of patients with CRF complicating hypertension.METHODS: CRF research group including 24 patients with CRF complicating hypertension receiving Valsartan 80mg/ d for 4 weeks; CRF control groups including 20 CRF patients with normal blood pressure; health group including 9 health people.The serum ET and CGRP levels, urinary protein, and Q - Td were measured.RESULTS: (l)The serum ET level of CRF patients was higher than that of health people;The serum ET level of CRF research group(before treatment) was higher than that of CRF control group and decreased after treatment of Valsartan.(2) The serum CGRP level of CRF patients was higher than that of health people .The serum of CGRP level of CRF research group (before treatment) was higher than that of CRF control group and continued to increase after treatment of Valsartan. (3) The content of urinary protein of CRF patients was significantly higher than that of health people.The content of urinary protien of CRF research group before treatment was higher than that of CRF control group and decreased after treatment of Valsartan. (4) The Q - Td of CRF research group was longer than that of health group and CRF control group.But the Q - Td of CRF research group did not change after treatment of Valsartan.CONCLUSION: Valsartan could effectively control blood pressure and decrease content of urinary protein, and delay the deterioration of renal function, but could not reverse the cardiovascular remoulding.
ABSTRACT
Objective:To study the change of Neuropeptide Y (NPY) plasma and its clinical si gnificance and the effects of Astragalus on NPY in plasma in chronic renal fail ure patients.Methods:Radioimmunoassay was used to measure plasma concentration of NPY.Results:①The plasma concentration of NPY in CRF patients was significantly high er than tha t in healthy group,and the plasma concentration of NPY in uremia patients was si gnificantly higher than that in nitremia patients.②The plasma concentration of NPY was positively correlated with the serum value of CRE and the level of MAP in CRF patients.③After Astraglus treatment for 3 weeks,the level of NPY in plas ma was significantly decreased in experiment group,but in control group,there wa s no significant change.Conclusion:The disturbance in synthesis,secretion or metabolism of NPY occurred in CRF patients,which significantly correlates with the occurrence and development of CRF.Astraglus can influence the NPY in plasma in CRF patients,so as to improve the renal function.